WO2003089624A3 - Fc receptor homolog, reagents, and uses thereof - Google Patents

Fc receptor homolog, reagents, and uses thereof Download PDF

Info

Publication number
WO2003089624A3
WO2003089624A3 PCT/US2003/009600 US0309600W WO03089624A3 WO 2003089624 A3 WO2003089624 A3 WO 2003089624A3 US 0309600 W US0309600 W US 0309600W WO 03089624 A3 WO03089624 A3 WO 03089624A3
Authority
WO
WIPO (PCT)
Prior art keywords
region
fcrh
subject
well
receptor
Prior art date
Application number
PCT/US2003/009600
Other languages
French (fr)
Other versions
WO2003089624A2 (en
Inventor
Randall S Davis
Max D Cooper
Original Assignee
Uab Research Foundation
Randall S Davis
Max D Cooper
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation, Randall S Davis, Max D Cooper filed Critical Uab Research Foundation
Priority to EP03738876A priority Critical patent/EP1490085A2/en
Priority to US10/508,374 priority patent/US7317087B2/en
Priority to JP2003586337A priority patent/JP2005521429A/en
Priority to AU2003245239A priority patent/AU2003245239A1/en
Priority to CA002480404A priority patent/CA2480404A1/en
Publication of WO2003089624A2 publication Critical patent/WO2003089624A2/en
Publication of WO2003089624A3 publication Critical patent/WO2003089624A3/en
Priority to US11/835,226 priority patent/US8648171B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs ('ITIMs' or 'ITAMs). The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the FcRHs as well as uses thereof. Such uses include uses in the diagnosis and treatment of a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject and in the modulation of a humoral immune response in a subject.
PCT/US2003/009600 2002-03-25 2003-03-25 Fc receptor homolog, reagents, and uses thereof WO2003089624A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP03738876A EP1490085A2 (en) 2002-03-25 2003-03-25 Fc receptor homolog, reagents, and uses thereof
US10/508,374 US7317087B2 (en) 2002-03-25 2003-03-25 Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof
JP2003586337A JP2005521429A (en) 2002-03-25 2003-03-25 Fc receptor homologues, reagents and uses thereof
AU2003245239A AU2003245239A1 (en) 2002-03-25 2003-03-25 FC receptor homolog, reagents, and uses thereof
CA002480404A CA2480404A1 (en) 2002-03-25 2003-03-25 Fc receptor homolog, reagents, and uses thereof
US11/835,226 US8648171B2 (en) 2002-03-25 2007-08-07 Members of the FC receptor homolog gene family (FcRH1-3,6) related reagents and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36766702P 2002-03-25 2002-03-25
US60/367,667 2002-03-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10508374 A-371-Of-International 2003-03-25
US11/835,226 Division US8648171B2 (en) 2002-03-25 2007-08-07 Members of the FC receptor homolog gene family (FcRH1-3,6) related reagents and uses thereof

Publications (2)

Publication Number Publication Date
WO2003089624A2 WO2003089624A2 (en) 2003-10-30
WO2003089624A3 true WO2003089624A3 (en) 2004-02-05

Family

ID=29250463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009600 WO2003089624A2 (en) 2002-03-25 2003-03-25 Fc receptor homolog, reagents, and uses thereof

Country Status (6)

Country Link
US (2) US7317087B2 (en)
EP (1) EP1490085A2 (en)
JP (1) JP2005521429A (en)
AU (1) AU2003245239A1 (en)
CA (1) CA2480404A1 (en)
WO (1) WO2003089624A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9475881B2 (en) 2010-01-19 2016-10-25 Xencor, Inc. Antibody variants with enhanced complement activity
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2003245239A1 (en) 2002-03-25 2003-11-03 Uab Research Foundation FC receptor homolog, reagents, and uses thereof
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1672065B1 (en) * 2003-09-29 2018-11-28 Chugai Seiyaku Kabushiki Kaisha Protein expressed in nk cell
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
AU2004308972C1 (en) * 2003-12-24 2009-11-26 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050266008A1 (en) * 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
BRPI0510883B8 (en) 2004-06-01 2021-05-25 Genentech Inc drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
RU2412947C2 (en) 2004-09-23 2011-02-27 Дженентек, Инк. Antibodies, constructed on cysteine basis and their conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US20080131433A1 (en) * 2004-09-27 2008-06-05 The Uab Research Foundation Fc Receptor Homolog Antibodies And Uses Thereof
EP1809670A4 (en) * 2004-09-29 2009-04-01 Medarex Inc Irta-4 antibodies and their uses
WO2006039238A2 (en) 2004-09-30 2006-04-13 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Irta2 antibodies and methods of use
WO2006053301A2 (en) 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
AU2006302254B2 (en) 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
RS53263B (en) 2006-08-14 2014-08-29 Xencor Inc. Optimized antibodies that target cd19
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
WO2008103905A2 (en) * 2007-02-23 2008-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies that specifically bind irta and methods of use
WO2009036283A2 (en) * 2007-09-14 2009-03-19 The Uab Research Foundation Differential diagnosis of b-cell chronic lymphocytic leukemia
SI2808343T1 (en) 2007-12-26 2019-10-30 Xencor Inc Fc variants with altered binding to FcRn
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
TWI540136B (en) 2010-04-15 2016-07-01 梅迪繆思有限公司 Pyrrolobenzodiazepines and conjugates thereof
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
JP5889912B2 (en) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド Alaninyl maytansinol antibody conjugate
JP5987053B2 (en) 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド Multiple reaction monitoring LC-MS / MS method for detecting therapeutic antibodies in animal samples using framework signature peptides
CN103987407B (en) 2011-10-14 2016-08-24 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and conjugate thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AU2013328628B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
RS58921B1 (en) 2012-10-12 2019-08-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
SI2906253T1 (en) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
DK2906296T3 (en) 2012-10-12 2018-05-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EA027910B1 (en) 2013-03-13 2017-09-29 Медимьюн Лимитед Pyrrolobenzodiazepines and conjugates thereof
MX362970B (en) 2013-03-13 2019-02-28 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof.
KR102066318B1 (en) 2013-03-13 2020-01-14 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015095223A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CA2929565A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CR20160271A (en) 2013-12-16 2016-12-02 Genentech Inc PEPTIDOMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN106714844B (en) 2014-09-12 2022-08-05 基因泰克公司 Anthracycline disulfide intermediates, antibody-drug conjugates and methods
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017533887A (en) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド Pyrrolobenzodiazepines and their antibody disulfide conjugates
BR112017011111A2 (en) 2014-11-25 2017-12-26 Adc Therapeutics Sa pyrrolobenzodiazepine-antibody conjugates
EP3226909A1 (en) 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (en) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド PROTAC antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
JP2020517609A (en) 2017-04-18 2020-06-18 メディミューン リミテッド Pyrrolobenzodiazepine complex
KR20190141666A (en) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 Combination Therapy with Anti-AXL Antibody-Drug Conjugates
MX2019015042A (en) 2017-06-14 2020-08-06 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc.
CN111065638B (en) 2017-08-18 2021-04-09 麦迪穆有限责任公司 Pyrrolobenzodiazepine conjugates
BR112020004307A2 (en) 2017-09-20 2020-11-10 Ph Pharma Co., Ltd. tailanestatin analogues
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113056287A (en) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 Conjugated chemical degradation inducers and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038490A2 (en) * 1999-11-29 2001-05-31 The Trustees Of Columbia University In The City Of New York ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA
US20030078396A1 (en) * 2000-03-01 2003-04-24 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1112395B (en) * 1979-03-23 1986-01-13 Giovanetti Fiorello JUNCTION DEVICE SUITABLE FOR JOINING TWO PIECES OR PANELS IN A REMOVABLE WAY
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3681787D1 (en) * 1985-07-05 1991-11-07 Whitehead Biomedical Inst EXPRESSION OF FOREIGN GENETIC MATERIAL IN EPITHELIC CELLS.
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
JP3082204B2 (en) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ Recombinant retrovirus with an amphotropic and ecotropic host range
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0703925B1 (en) 1993-06-03 1999-08-18 Therapeutic Antibodies Inc. Production of antibody fragments
US20040034192A1 (en) * 2000-01-06 2004-02-19 Seishi Kato Human proteins having hyprophobic domains and dnas encoding these proteins
EP1201681A1 (en) * 2000-10-30 2002-05-02 Millennium Pharmaceuticals, Inc. "Fail" molecules and uses thereof
AU2003245239A1 (en) 2002-03-25 2003-11-03 Uab Research Foundation FC receptor homolog, reagents, and uses thereof
AU2004308972C1 (en) 2003-12-24 2009-11-26 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20080131433A1 (en) 2004-09-27 2008-06-05 The Uab Research Foundation Fc Receptor Homolog Antibodies And Uses Thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038490A2 (en) * 1999-11-29 2001-05-31 The Trustees Of Columbia University In The City Of New York ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA
US20030078396A1 (en) * 2000-03-01 2003-04-24 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CARLSSON ET AL.: "Expression of GcgammaRIII defines distinct subpopulations of fetalk liver B cell and myeloid precursors", EUR J. IMMUNOL., vol. 25, no. 8, August 1995 (1995-08-01), pages 2308 - 2317, XP002971666 *
DAVIS R.S. ET AL.: "Fc receptor homologs: Newest members of a remarkably diverse Fc receptor gene family", IMMUNOLOGICAL REVIEWS, vol. 190, 2002, pages 123 - 136, XP002971663 *
DAVIS R.S. ET AL.: "Identification of a family of Fc receptor homologs with preferential B cell expression", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 17, 14 August 2001 (2001-08-14), pages 9772 - 9777, XP002971662 *
KANT A.M. ET AL.: "Heterogeneity in the expression of FcgammaRIII in morphologically mature granulocytes from patients with chronic myeloid leukemia", LEUKEMIA RESEARCH, vol. 21, no. 3, March 1997 (1997-03-01), pages 225 - 234, XP002971664 *
MORTON H.C. ET AL.: "Alternatively spliced forms of the human myeloid Fcalpha receptor (CD89) in neutrophils", IMMUNOGENETICS, vol. 43, no. 4, 1996, pages 246 - 247, XP002971665 *
MORTON H.C. ET AL.: "Structure and function of human IgA Fc receptors (FcalphaR)", CRITICAL REVIEWS IN IMMUNOLOGY, vol. 16, no. 4, 1996, pages 423 - 440, XP002066873 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9475881B2 (en) 2010-01-19 2016-10-25 Xencor, Inc. Antibody variants with enhanced complement activity
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
AU2003245239A1 (en) 2003-11-03
US7317087B2 (en) 2008-01-08
CA2480404A1 (en) 2003-10-30
EP1490085A2 (en) 2004-12-29
US8648171B2 (en) 2014-02-11
WO2003089624A2 (en) 2003-10-30
JP2005521429A (en) 2005-07-21
US20050240006A1 (en) 2005-10-27
US20080089887A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
WO2003089624A3 (en) Fc receptor homolog, reagents, and uses thereof
Lanier Turning on natural killer cells
Yokoyama et al. Immune functions encoded by the natural killer gene complex
Choi et al. Residues of the variable region of the T-cell-receptor β-chain that interact with S. aureus toxin superantigens
Miller et al. IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells
Ho et al. Costimulation of multiple NK cell activation receptors by NKG2D
Vilches et al. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity
Yokoyama Natural killer cell receptors
Lanier Face off—the interplay between activating and inhibitory immune receptors
Stamenkovic et al. The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion
Sivori et al. Inhibitory receptors and checkpoints in human NK cells, implications for the immunotherapy of cancer
Bashirova et al. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense
Colonna et al. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells
Pessino et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity
Allan et al. Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells
Hershberger et al. Diversity of the killer cell Ig-like receptors of rhesus monkeys
Williams et al. The immunoglobulin superfamily—domains for cell surface recognition
Leibson Signal transduction during natural killer cell activation: inside the mind of a killer
Winter et al. A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes.
Lopez-Cabrera et al. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors.
Mariuzza et al. Structural basis for recognition of cellular and viral ligands by NK cell receptors
Matsumoto et al. The functional binding site for the C-type lectin–like natural killer cell receptor Ly49a spans three domains of its major histocompatibility complex class I ligand
Torkar et al. Isotypic variation of novel immunoglobulin‐like transcript/killer cell inhibitory receptor loci in the leukocyte receptor complex
Call et al. Common themes in the assembly and architecture of activating immune receptors
CN102131517B (en) Soluble hybrid fc gamma receptors and related methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003245239

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003586337

Country of ref document: JP

Ref document number: 2480404

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003738876

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003738876

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10508374

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003738876

Country of ref document: EP